Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Benefits of Intensity Modulated Radiotherapy for Advanced Lung Cancer
1
Mins
July 2024
New findings have provided crucial insights into the optimal radiotherapy techniques for treating unresectable locally advanced non–small cell lung cancer.
Read more
1
Mins
18th May 2015
Are YOU at Increased Risk of Leukaemia?
INCREASED risk of acute lymphoblastic leukaemia (ALL) can be attributed to a genetic mutation in a similar manner to the BRCA1 mutation that can…
1
Mins
18th May 2015
Rise in Deadly Skin Cancer is by No Means Old News
SENIOR citizens in Britain are approximately seven times more likely to develop malignant melanoma than they were 40 years ago, according to new statistics.
5
Mins
11th May 2015
The Scottish Medicines Consortium Approves Gilead’s Zydelig® q (Idelalisib) for the Treatment of Follicular Lymphoma That Is Refractory to Two Prior Lines of Treatment in Adult Patients
Foster City, CA, 11 May 2015 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Scottish Medicines Consortium (SMC) has approved Zydelig…
2
Mins
17th April 2015
One in Four Advanced Lung Cancer Patients Tested for EGFR Mutations Started on First-Line Treatment Before Test Results Available
Geneva, Switzerland, 17 April 2015 — Almost one in four patients (24%) with advanced lung cancer in Europe, Asia and the US are not receiving…
2
Mins
17th April 2015
Evidence Grows That Melanoma Drugs Benefit Some Lung Cancer Patients
Geneva, Switzerland, 17 April 2015 — A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to…
2
Mins
17th April 2015
New Real-World Clinical Practice Study Highlights the Value of the Oncotype DX® Breast Cancer Test for Patients, Physicians and the Health Care System
Studies present results from a real-life observational study in Ireland demonstrating significant reductions in chemotherapy and resulting cost-savings when the test is used in early stage breast cancer.
2
Mins
25th February 2015
Living with a Rare Cancer
Lugano, 25 February 2015 – Within the “umbrella” of rare diseases, rare cancer patients confront particular problems. Most rare diseases have an…
1
Mins
23rd February 2015
Combination Therapy Trial for Breast Cancer
BREAST cancer patients with small node-negative HER2-positive tumours achieved 3-year survival approaching 100% with adjuvant paclitaxel and trastuzumab…
Loading posts...
« Previous
1
…
28
29
30
31
32
Next »